Stryker (NYSE:SYK) Shares Gap Up After Better-Than-Expected Earnings

Stryker Corporation (NYSE:SYK) gapped up prior to trading on Friday following a better than expected earnings announcement. The stock had previously closed at $354.30, but opened at $369.10. Stryker shares last traded at $368.9750, with a volume of 371,383 shares traded.

The medical technology company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.73% and a net margin of 12.92%.The company had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same period in the previous year, the company posted $4.01 EPS. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st were issued a $0.88 dividend. This is an increase from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Wednesday, December 31st. Stryker’s dividend payout ratio is presently 46.25%.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Q4 results beat estimates — adjusted EPS $4.47 vs. $4.40 consensus and revenue of $7.17B (organic growth ~11%), with management citing strong Mako adoption as a growth driver. SYK Stock Gains as Q4 Earnings & Sales Beat on Strong Mako Adoption
• Positive Sentiment: Company raised its full‑year profit forecast and reported record revenue (>$25B FY2025) with adjusted operating margin expansion — supports upside to earnings expectations. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Analysts are raising targets and reiterating buy ratings — Needham bumped its price target to $454 and reiterated Buy, reinforcing broker support after the print. SYK: Stryker price target raised by Needham Stryker: Sustained Double‑Digit Growth and Operating Leverage Support Buy Rating
• Neutral Sentiment: 2026 guidance: management expects 8.0%–9.5% organic sales growth and adjusted EPS $14.90–$15.10 (roughly in line with street consensus); guidance shows continued growth but is narrowly ranged. Stryker projects 8%–9.5% organic sales growth for 2026
• Neutral Sentiment: Operating performance detail — adjusted operating margin widened ~100 bps to 30.2% in Q4 and management emphasizes margin expansion and new product launches as 2026 drivers. Stryker reports 2025 operating results and 2026 outlook
• Negative Sentiment: Headwinds and risks flagged — analysts and the company note possible 2026 tariff pressures, regulatory and macro risks that could constrain upside; keep an eye on cost/price dynamics and geopolitics. Stryker: Sustained Double‑Digit Growth and Operating Leverage Support Buy Rating
• Negative Sentiment: Insider selling activity flagged in some data summaries — notable executive/insider sales were reported which some investors monitor as a negative signal (context and timing matter). Stryker Reports Strong Q4 and Full‑Year 2025 Results (Quiver summary)

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on SYK. Raymond James Financial upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target on the stock in a research note on Tuesday, January 6th. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Saturday. UBS Group set a $408.00 target price on Stryker in a research note on Monday, October 13th. Barclays boosted their price target on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Finally, Citigroup reiterated a “market outperform” rating on shares of Stryker in a research report on Friday. Twelve research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $426.95.

Insider Activity

In other news, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This represents a 9.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. This trade represents a 40.81% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 522,118 shares of company stock worth $185,381,932. 5.90% of the stock is currently owned by company insiders.

Institutional Trading of Stryker

Several large investors have recently made changes to their positions in the company. Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Stryker in the 2nd quarter valued at $26,000. Clayton Financial Group LLC acquired a new stake in Stryker in the third quarter valued at about $26,000. United Financial Planning Group LLC acquired a new stake in Stryker in the third quarter valued at about $27,000. Elevation Point Wealth Partners LLC bought a new position in Stryker in the second quarter valued at about $28,000. Finally, Sachetta LLC raised its stake in Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

The business’s fifty day moving average price is $359.40 and its 200 day moving average price is $371.66. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. The stock has a market cap of $141.26 billion, a P/E ratio of 43.97, a PEG ratio of 2.27 and a beta of 0.89.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.